Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: The possible role of leukotrienes

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 2, 2003, Pages 131-140

  Storms, William W ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; HISTAMINE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PEPTIDOLEUKOTRIENE;

ALLERGIC RHINITIS; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; HUMAN; IMMUNOTHERAPY; INFLAMMATION; NOSE CONGESTION; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; REVIEW; RHINORRHEA; SNEEZING; SYMPTOMATOLOGY; TREATMENT PLANNING;

EID: 0042739193     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62167-9     Document Type: Review

References (68)

1. Nimmagadda SR, Evans R 3rd. Allergy: etiology and epidemiology. Pediatr Rev. 1999;20:111-116.
2. Ceuppens J. Western lifestyle, local defenses and the rising incidence of allergic rhinitis. Acta Otorhinolaryngol Belg. 2000;54:391-395.
3. Nathan RA, Meltzer EO, Selner JC, Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997;99:S808-S814.
4. Hendershot G, Adams P, Marano M. Current estimates from the national health interview survey, 1996. Centers for Disease Control and Prevention/National Center for Health Statistics. Vital Health Stat. 1999;10(200).
5. Ma X, Fick RB, Kaplowitz HJ. Prevalence of allergic rhinoconjunctivitis in the United States: data from the third National Health and Nutrition examination survey, 1988-94 (NHANES III). Am J Respir Crit Care Med. 2000;161:A325.
6. Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics. 1994;94:895-901.
7. Arrighi HM, Maier WC, Redding GJ, Morray B. The impact of allergic rhinitis in Seattle school children. J Allergy Clin Immunol. 1995;95:192.
8. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy. 1994;73:35-39.
9. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999;103:401-407.
10. Schering-Plough. Available at: http://www.sch-plough.com/documents/allergy.pdf. Accessed July 26, 2002.
11. Aventis. Available at: http://www.aventis.com/aventisfilearchive/docs/8/doc0000026312.pdf. Accessed July 26, 2002.
12. GlaxoSmithKline. Available at: http://www.gsk.com/financial/reports/ar2001/annual-report-01/gskrep30.html. Accessed July 26, 2002.
13. Pfizer. Available at: http://www.pfizer.com/pfizerinc/investing/pfizer2001.pdf. Accessed July 26, 2002.
14. Smith JM. Epidemiology and natural history of asthma, allergic rhinitis, and atopic dermatitis (eczema). In: Middleton EJ, Reed CE, Ellis E, Adkinson NF, Yunginger JW, editors. Allergy: Principles and Practice. Chapter 39, St. Louis, MO: Mosby; 1988:891-929.
15. Juliusson S, Pipkorn U, Karlsson G, Enerback L. Mast cells and eosinophils in the allergic mucosal response to allergen challenge: changes in distribution and signs of activation in relation to symptoms. J Allergy Clin Immunol. 1992;90:898-909.
16. Bjornsdottir US, Cypcar DM. Asthma: an inflammatory mediator soup. Allergy. 1999;54:55-61.
17. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789-793.
18. + hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1. Blood. 2001;97:3433-3440.
19. +/interleukin-5Rα messenger RNA+ cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors. Am J Respir Cell Mol Biol. 1999;20:9-13.
20. 4 on endothelin-1 and prostacyclin release by cultured vascular cells. Pharmacol Res. 1993;27:281-285.
21. 4. Potentiation of inflammation. Am J Respir Cell Mol Biol. 2000;23:572-577.
22. Pedersen KE, Bochner BS, Undem BJ. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther. 1997;281:655-662.
23. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med. 1998;157:1381-1389.
24. + T cell-driven late allergic airway responses. J Pharmacol Exp Ther. 2000;293:410-416.
25. 4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells. Am J Physiol. 1996;271:L1014-L1022.
26. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med. 1999;160:1227-1231.
27. Steinhilber D, Radmark O, Samuelsson B. Transforming growth factor beta upregulates 5-lipoxygenase activity during myeloid cell maturation. Proc Natl Acad Sci USA. 1993;90:5984-5988.
28. Pynaert G, Grooten J, van Deventer SJ, Peppelenbosch MP. Cysteinyl leukotrienes mediate histamine hypersensitivity ex vivo by increasing histamine receptor numbers. Mol Med. 1999;5:685-692.
29. Cowburn AS, Holgate ST, Sampson AP, IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. J Immunol. 1999;163:456-465.
30. Hsieh FH, Lam BK, Penrose JF, Austen KF, Boyce JA. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells. Profound induction of leukotriene c(4) synthase expression by interleukin 4. J Exp Med. 2001;193:123-134.
31. Brock TG, McNish RW, Coffey MJ, Oja TC, Phare SM, Peters-Golden M. Effects of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. J Immunol. 1996;156:2522-2527.
32. 4 from mouse bone marrow-derived mast cells. Eur J Pharmacol. 1994;257:235-242.
33. Rasp G, Thomas PA, Bujia J. Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhinitis measured by eosinophil cationic protein levels in native nasal fluid and serum. Clin Exp Allergy. 1994;24:1151-1156.
34. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med. 2000;161:1881-1886.
35. White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol. 1992;90:699-704.
36. 4 in allergic rhinitis. Ann Allergy. 1988;60:537-540.
37. Svensson C, Baumgarten CR, Pipkorn U, Alkner U, Persson CG. Reversibility and reproducibility of histamine induced plasma leakage in nasal airways. Thorax. 1989;44:131-8.
38. Rajakulasingam K, Polosa R, Lau LC, Church MK, Holgate ST, Howarth PH. Comparative nasal effects of bradykinin and histamine: influence on nasal airways resistance and plasma protein exudation. Thorax. 1993;48:324-329.
39. Djukanovic R, Wilson SJ, Howarth PH. Pathology of rhinitis and bronchial asthma. Clin Exp Allergy 1996;26(Suppl):44-51.
40. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy. 1986;16:289-297.
41. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy. 1997;52:12-18.
42. 4 in grass pollen-induced rhinitis. Am Rev Respir Dis. 1987;136:357-362.
43. Creticos PS, Peters SP, Adkinson NF Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med. 1984;310:1626-1630.
44. Wang D, Clement P, Smitz J, Derde MP. Concentrations of chemical mediators in nasal secretions of patients with hay fever during natural allergen exposure. Acta Otolaryngol. 1994;114:552-555.
45. 4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341:989-990.
46. 4) on motility of isolated normodense human eosinophils and neutrophils. Adv Exp Med Biol. 1997;400B:699-706.
47. Proud D, Reynolds CJ, Lacapra S, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis. 1988;137:613-616.
48. Doyle WJ, Boehm S, Skoner DP. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol. 1990;86:924-935.
49. Devillier P, Dessanges JF, Rakotosihanaka F, et al. Nasal response to substance P and methacholine in subjects with and without allergic rhinitis. Eur Respir J. 1988;1:356-361.
50. Passalaqua G, Canonica GW. Impact of rhinitis on airway inflammation: biological and therapeutic implications. Respir Res. 2001;2:320-323.
51. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
52. Ricca V, Landi M, Ferrero P, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;105:54-57.
53. Ciprandi G, Buscaglia S, Pesce G, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol. 1995;96:971-979.
54. Gaga M, Lambrou P, Papageorgiou N, et al. Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy. 2000;30:663-669.
55. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol. 1992;89:611-618.
56. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol. 2001;107:469-476.
57. Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med. 2000;161:2051-2057.
58. Wang D, Duyck F, Smitz J, Clement P. Efficacy and onset of action of fluticasone propionate aqueous nasal spray on nasal symptoms, eosinophil count, and mediator release after nasal allergen challenge in patients with seasonal allergic rhinitis. Allergy. 1998;53:375-382.
59. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995;151:1734-1739.
60. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020-1028.
61. Philip G, Malmstrom K, LaForce CF, Malice MP, Reiss TF. Montelukast in the treatment of nighttime symptoms associated with spring allergic rhinitis in a double-blind, randomized, placebo-controlled study. Paper presented at: The XXth Congress of the European Academy of Allergology and Clinical Immunology; May 9-13, 2001; Berlin, Germany. Allergy. 2001;56.
62. Michele TM, Lu S, Malice MP, et al. Combination of montelukast and loratadine in seasonal allergic rhinitis: an analysis of three spring studies. J Allergy Clin Immunol. 2000;105:S387.
63. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88:592-600.
64. Philip G, Malmstrom K, Nayak A, Malice MP, Reiss TF. Improvement in rhinoconjunctivitis quality of life outcomes in the treatment of fall allergic rhinitis by montelukast alone or in combination with loratadine in a multicenter, double-blind, randomized, placebo-controlled study. J Allergy Clin Immunol. 2001;107:S158.
65. Numata T, Konno A, Yamakoshi T, Hanazawa T, Terada N, Nagata H. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol. 1999;108:467-473.
66. Ciprandi G, Ricca V, Passalacqua G, et al. Seasonal rhinitis and azelastine: long- or short-term treatment? J Allergy Clin Immunol. 1997;99:301-307.
67. Ciprandi G, Passalacqua G, Mincarini M, Ricca V, Canonica GW. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79:507-511.
68. Drazen JM, Boccuzzi SJ, Wogen J, et al. Adherence to prescribed treatment for asthma. Am J Respir Crit Care Med. 2000;161:A402.